A federal judge is examining whether the Pentagon's new testosterone initiative affects its legal defense of restrictions on transgender troops. U.S. District Judge Ana C. Reyes raised concerns about War Secretary Pete Hegseth's announcement that troops aged 30 and older would be screened for testosterone deficiency and could receive testosterone replacement therapy (TRT). Reyes, overseeing the case Talbott v. Trump, stated that the new policy could influence the government's justification for the existing restrictions on transgender service members.
Reyes ordered both parties in the case to address various aspects of the TRT policy, including screening and monitoring processes. The government has historically argued against providing hormone treatments for military members with gender dysphoria while promoting similar treatments for others. In a previous filing, the Trump administration cited the military's need for deployable troops without requiring routine medical treatment as a reason for the ban on transgender troops.
The introduction of TRT for testosterone deficiency could challenge these arguments, although it does not eliminate the administration's legal position. Critics suggest that the TRT initiative may imply that hormone treatment is not necessarily incompatible with military readiness. The government has also raised concerns about privacy, physical fitness standards, and unit cohesion regarding transgender service members.
Reyes's order adds pressure on the government's medical rationale in the case, as it may struggle to justify the differential treatment of hormone therapies. Both parties have been instructed to prepare briefs by August 7 to discuss how the Supreme Court's ruling in B.P.J. v. West Virginia relates to the ongoing dispute over the transgender troops executive order. The ban on transgender individuals seeking to join the military remains in effect despite legal challenges against the Pentagon's policy.